ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3029% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
ADMA Biologics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
ADMA Biologics's price to book ratio was 7.3× on Nov 11, 2026, against 10.6× a year earlier. Over the last 5 years it ranged from 1.9× to 24.7×, with a median of 6.7×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.3× | −2.8 |
| 2025 | Dec 31, 2025 | 10.1× | −7.4 |
| 2024 | Dec 31, 2024 | 17.5× | +10.7 |
| 2023 | Dec 29, 2023 | 6.7× | −0.9 |
| 2022 | Dec 30, 2022 | 7.6× | +5.7 |
| 2021 | Dec 31, 2021 | 1.9× | −0.6 |
| 2020 | Dec 31, 2020 | 2.4× | −4.1 |
| 2019 | Dec 31, 2019 | 6.6× | +3.6 |
| 2018 | Dec 31, 2018 | 3.0× | −1.3 |
| 2017 | Dec 29, 2017 | 4.3× | −14.1 |
| 2016 | Oct 31, 2016 | 18.4× | +0.8 |
| 2015 | Dec 31, 2015 | 17.6× | +6.4 |
| 2014 | Dec 31, 2014 | 11.2× | −17.0 |
| 2013 | Oct 31, 2013 | 28.2× | – |
See a number that looks wrong?